About: Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 08 November 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 2018 (uk) article scientifique publié en 2018 (fr) im November 2018 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en payares de 2018 (ast) scientific article published on 08 November 2018 (en)
publication date	wds:Q92985120-07E1A3A3-8CEB-4FE2-A405-070DFBC87B85
publication date	2018-11-08 00:00:00Z (xsd:dateTime)
cites work	wds:Q92985120-00543FEC-4FD3-45CA-8D9A-6D50E6C6DF95 wds:Q92985120-3375AA2F-C65E-40A8-8C62-D01098331F6F wds:Q92985120-5044B935-F815-4247-88E9-19DB5E3A7E30 wds:Q92985120-587DA0F0-A045-4C3A-9988-7ABE09F311F9 wds:Q92985120-6250ABB1-6538-400A-84D6-5EDE6600D01A wds:Q92985120-6C1DDF85-3ABA-4748-A998-F5873DFDCCCB wds:Q92985120-8C2D1A6E-ACCC-4290-A326-72FA7AA6C3A3 wds:Q92985120-94356B3F-6B63-4B39-B61A-DDDA9221367B wds:Q92985120-B79242DB-1369-49CD-A300-15E33207C206 wds:Q92985120-BA9638A1-54FD-47FF-BD81-4A86C8A61CE2 wds:Q92985120-BF8394AE-8EB2-4A44-A6CD-BDA6143425A7 wds:Q92985120-CEEC8840-DA72-4078-B3B1-1B049401B7A6 wds:Q92985120-E825C5B9-3584-4880-AF29-11BA5289CCC1 wds:Q92985120-F9C53117-4758-4E5C-93B9-1B1EFA115602
cites work	Global asthma prevalence in adults: findings from the cross-sectional world health survey International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function The poorly explored impact of uncontrolled asthma The consequences of not having eosinophils. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study Tissue and BAL based biomarkers in asthma Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Biologic therapies targeting eosinophils: current status and future prospects
author name string	wds:Q92985120-035653C2-4537-40C6-B5A8-56C4A00725D2 wds:Q92985120-2A2E655E-AF0B-4E05-995C-42C84B58A723 wds:Q92985120-2D5DA2F5-32FD-4DA3-9077-F842A9621FFB wds:Q92985120-504132DA-5027-41E6-A672-0A2F85ABF1A4 wds:Q92985120-60C58307-6227-4D99-87EF-AC83A946EEF5 wds:Q92985120-652743B1-6F43-4EEC-BFF3-812C85E78E52 wds:Q92985120-BCE08857-2878-4FB8-8FA0-809AB0531C0A wds:Q92985120-C6CDD124-CFEC-415A-A50C-49B627FB7A90 wds:Q92985120-E8C0EAA3-E3B7-4B83-A291-CEFDC97396EE
author name string	Peter Barker Eugene R Bleecker William W Busse J Mark FitzGerald Gary T Ferguson Ubaldo J Martin Mitchell Goldman BORA study investigators Stephanie Sproule
rdfs:label	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial (en) Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial (nl)
skos:prefLabel	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial (en) Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial (nl)
name	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial (en) Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial (nl)
author	wds:Q92985120-FCDDAF28-18F9-4E24-9A9C-1CF5140B7E17
author	Richard Olsson
title	wds:Q92985120-3F2F7330-C12B-49A5-8E13-073869B9E30E
title	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial (en)
page(s)	wds:Q92985120-CDC38E5E-2541-45FE-8C02-C5B14DFA0A87
page(s)	46-59
instance of	wds:Q92985120-29963F72-3662-45F8-9ADD-6E712D4A18BE
instance of	scholarly article
main subject	wds:Q92985120-0B94541F-56A4-46FF-BE19-EE70235F685C wds:Q92985120-F6776786-959A-443B-841D-4FA412222869
main subject	asthma phase III clinical trial
PubMed ID	wds:Q92985120-B0840011-107D-4887-8CC8-FC15479B2817
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30416083
PubMed ID	30416083
published in	wds:Q92985120-5C809ABC-3FE3-45AF-AF14-6963950FE627
published in	The Lancet. Respiratory medicine
issue	wds:Q92985120-C98136F7-EAEC-4910-B8F3-179FB7654EB7
volume	wds:Q92985120-5F26E9FA-9910-4C20-893A-FE60D3E97AE1
issue	1
volume	7
DOI	wds:Q92985120-E91C921E-9046-4021-9128-838E0077787D
DOI	http://dx.doi.org/10.1016/S2213-2600(18)30406-5
DOI	10.1016/S2213-2600(18)30406-5
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q92985120
is cites work of	2020 Brazilian Thoracic Association recommendations for the management of asthma Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis Interleukin-5 in the Pathophysiology of Severe Asthma Severe Eosinophilic Asthma Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets Severe Asthma and Biological Therapy: When, Which, and for Whom COVID-19, asthma, and biologic therapies: What we need to know Targeting eosinophils: severe asthma and beyond New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software